That's not the real BAD typo. You need to correct the one in your title.
Do you think that maybe it's because Gilead and Celgene might be growing their revenues faster?
The rival drug was JNJs Procrit. It happened last decade. It has nothing to do with Omontys. JNJ was playing a similar game with Amgen. To learn more, read the book "Blood Feud".
Give the guy a break. He came from Morgan Stanley to Amgen. He no way of knowing that he is getting paid way too much!
Genentech doesn't exist anymore as an independent entity. It is a division of Roche.
Only Novartis and Roche are big enough to buy Amgen. 90 billion is a big bite to chew even for them. It would have to be a mostly stock deal, IMO. So we'll see. I'm skeptical.
I've been through the previous splits so I know where you're coming from. I just don't think it'll happen this time. Attracting individual investors isn't that important to big corporations and Wall Street. JMHO! In any event, Apple and Google showed that you don't have to split to attract investors. Sure, some old guys like us remember that you needed a round lot to get a good price on a market order. But you can buy any number you want on Scottrade electronically and get it filled at a good price. If there is a split, it'll be decided at the BOD meeting in April and then you can laugh all you want!
Stock splits are no longer in fashion on Wall Street.